The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
Open accessAbstract
BACKGROUND: Secukinumab, a fully human immunoglobulin G1-kappa monoclonal antibody that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in the treatment of moderate-to-severe psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) demonstrating a rapid onset of action and sustained long-term clinical responses with a consistently favorable safety profile in multiple Phase 2 and 3 trials. Here, we report longer-term pooled safety and tolerability data for secukinumab across three indications (up to 5 years of treatment in PsO and PsA; up to 4 years in AS). METHODS: The integrated clinical trial safety dataset included data pooled from 21 randomized controlled clinical trials of secukinumab 300 or 150 or 75 mg in PsO (14 Phase 3 trials and 1 Phase 4 trial), PsA (3 Phase 3 trials), and AS (3 Phase 3 trials), along with post-marketing safety surveillance data with a cut-off date of June 25, 2017. Adverse events (AEs) were reported as exposure-adjusted incident rates (EAIRs) per 100 patient-years. Analyses included all patients who received ≥ 1 dose of secukinumab. RESULTS: A total of 5181, 1380, and 794 patients from PsO, PsA, and AS clinical trials representing secukinumab exposures of 10,416.9, 3866.9, and 1943.1 patient-years, respectively, and post-marketing data from patients with a cumulative exposure to secukinumab of ~ 96,054 patient-years were included in the analysis. The most frequent AE was upper respiratory tract infection. EAIRs across PsO, PsA, and AS indications were generally low for serious infections (1.4, 1.9, and 1.2, respectively), Candida infections (2.2, 1.5, and 0.7, respectively), inflammatory bowel disease (0.01, 0.05, and 0.1, respectively), and major adverse cardiac events (0.3, 0.4, and 0.6, respectively). No cases of tuberculosis reactivation were reported. The incidence of treatment-emergent anti-drug antibodies was low with secukinumab across all studies, with no discernible loss of efficacy, unexpected alterations in pharmacokinetics, or association with immunogenicity-related AEs. CONCLUSIONS: Secukinumab demonstrated a favorable safety profile over long-term treatment in patients with PsO, PsA, and AS. This comprehensive assessment demonstrated that the safety profile of secukinumab was consistent with previous reports in patients with PsO, PsA, and AS, supporting its long-term use in these chronic conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Recognition of microorganisms and activation of the immune response
Medzhitov, R. (2007) · Nature · doi:10.1038/nature06246 · Cited by 2,862
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997 · cited 1×
“The rates were comparable with those reported previously [15, 16, 18, 20], and no new safety signals were identified from those reported previously.”
The Electronic Medical Records and Genomics (eMERGE) Consortium, Wood, A. R., The MIGen Consortium, The PAGE Consortium, Study, T. L. C., Esko, T., Yang, J., Vedantam, S., Pers, T. H., Gustafsson, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.3097 · Cited by 1,853 · cited 1×
“All treatment-emergent ADAs were associated with normal PK [30], and none were associated with loss of secukinumab efficacy or immunogenicity-related AEs.”
IL-17 family cytokines and the expanding diversity of effector T cell lineages
Weaver, C. T., Hatton, R. D., Mangan, P. R., & Harrington, L. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141557 · Cited by 1,842
Epidemiology and risk factors for IBD
Ananthakrishnan, A. N. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.34 · Cited by 1,741
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505066 · Cited by 1,029
Self-citationPhagocytosis of Apoptotic Neutrophils Regulates Granulopoiesis via IL-23 and IL-17
Stark, M. A., Huo, Y., Burcin, T. L., Morris, M. A., Olson, T. S., & Ley, K. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.011 · Cited by 947
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Self-citationBaecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., Catrina, A. I., Rosenquist, R., Feltelius, N., Sundström, C., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21675 · Cited by 890
Hueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
McInnes, I. B., Mease, P. J., Kirkham, B., Kavanaugh, A., Ritchlin, C. T., Rahman, P., van der Heijde, D., Landewé, R., Conaghan, P. G., Gottlieb, A. B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61134-5 · Cited by 858
Self-citationThe Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Blauvelt, A., & Chiricozzi, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8702-3 · Cited by 789
Self-citationSecukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Mease, P. J., McInnes, I. B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., Landewé, R., Nash, P., Pricop, L., Yuan, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412679 · Cited by 746
Self-citationBaeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J. M., Landewé, R., Wordsworth, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61134-4 · Cited by 595
Self-citationThaçi, D., Blauvelt, A., Reich, K., Tsai, T.-F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.013 · Cited by 551
Self-citationKalb, R. E., Fiorentino, D. F., Lebwohl, M. G., Toole, J., Poulin, Y., Cohen, A. D., Goyal, K., Fakharzadeh, S., Calabro, S., Chevrier, M., et al. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.0718 · Cited by 373
Self-citationBlauvelt, A., Prinz, J. C., Gottlieb, A. B., Kingo, K., Sofen, H., Ruer-Mulard, M., Singh, V., Pathan, R., Papavassilis, C., Cooper, S., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13348 · Cited by 323
Self-citationEffect of IL-17A blockade with secukinumab in autoimmune diseases
Patel, D. D., Lee, D. M., Kolbinger, F., & Antoni, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202371 · Cited by 313
Blauvelt, A., Reich, K., Tsai, T.-F., Tyring, S., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Vender, R., Hugot, S., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.008 · Cited by 312
Self-citationvan de Kerkhof, P. C. M., Griffiths, C. E. M., Reich, K., Leonardi, C. L., Blauvelt, A., Tsai, T.-F., Gong, Y., Huang, J., Papavassilis, C., & Fox, T. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.03.024 · Cited by 302
Self-citationThe Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
Furst, D. E. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.10.002 · Cited by 291
Paul, C., Lacour, J. ‐., Tedremets, L., Kreutzer, K., Jazayeri, S., Adams, S., Guindon, C., You, R., Papavassilis, C., & the JUNCTURE study group (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12751 · Cited by 280
Mrowietz, U., Leonardi, C. L., Girolomoni, G., Toth, D., Morita, A., Balki, S. A., Szepietowski, J. C., Regnault, P., Thurston, H., & Papavassilis, C. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.04.011 · Cited by 208
Self-citationGisbert, J. P., Marín, A. C., & Chaparro, M. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.54 · Cited by 204
Wan, J., Wang, S., Haynes, K., Denburg, M. R., Shin, D. B., & Gelfand, J. M. (2013) · BMJ · doi:10.1136/bmj.f5961 · Cited by 202
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Lebwohl, M. G., Papp, K. A., Marangell, L. B., Koo, J., Blauvelt, A., Gooderham, M., Wu, J. J., Rastogi, S., Harris, S., Pillai, R., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.024 · Cited by 179 · cited 1×
“There was no evidence to suggest that treatment with secukinumab increases the risk of suicidality-related AEs beyond background risk in patients with these systemic inflammatory diseases [45, 46].”
Self-citationHueber, W., Patel, D. D., Dryja, T. P., Wright, A., Bruin, G. J. M., Antoni, C., Gold, M. H., Durez, P., Tak, P. P., Go, J. J., et al. (2010) · Cited by 151
Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study
Egeberg, A., Mallbris, L., Warren, R. B., Bachelez, H., Gislason, G., Hansen, P. R., & Skov, L. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14528 · Cited by 150
McInnes, I. B., Mease, P. J., Ritchlin, C. T., Rahman, P., Gottlieb, A. B., Kirkham, B. W., Kajekar, R., Delicha, E.-M., Pricop, L., & Mpofu, S. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex301 · Cited by 148
Self-citationWu, J. J., Penfold, R. B., Primatesta, P., Fox, T., Stewart, C. C., Reddy, S. P., Egeberg, A., Liu, J., & Simon, G. E. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14175 · Cited by 133
Self-citationWakkee, M., de Vries, E., van den Haak, P., & Nijsten, T. E. C. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.08.036 · Cited by 114
Warren, R. B., Reich, K., Langley, R. G. B., Strober, B. E., Gladman, D. D., Deodhar, A. A., Bachhuber, T., Bao, W., Altemeyer, E., Hussain, S. S. H., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16901 · Cited by 106
Self-citationFrom Inflammation to Cancer in Inflammatory Bowel Disease: Molecular Perspectives.
Romano, M., Francesco, F. D., Zarantonello, L., Ruffolo, C., Ferraro, G. A., Zanus, G., Giordano, A., Bassi, N., & Cillo, U. (2016) · PubMed · Cited by 105
Immunogenicity of biologic therapies: causes and consequences
Boehncke, W., & Brembilla, N. C. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1468753 · Cited by 87
Lauper, K., Courvoisier, D. S., Chevallier-Ruggeri, P., Finckh, A., & Gabay, C. (2018) · Arthritis Care & Research · doi:10.1002/acr.23567 · Cited by 75
Hsu, L., & Armstrong, A. W. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2013.836060 · Cited by 70
Fragility of epidermis in newborns, children and adolescents
Blume‐Peytavi, U., Tan, J. K. L., Tennstedt, D., Boralévi, F., Fabbrocini, G., Torrelo, A., Soares‐Oliveira, R., Haftek, M., Rossi, A. B., Thouvenin, M., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13636 · Cited by 70
The potential of interleukin-17 to mediate hematopoietic response
Krstić, J., Mojsilović, S. B., Jovčić, G., & Bugarski, D. S. (2012) · Immunologic Research · doi:10.1007/s12026-012-8276-8 · Cited by 64
Hypersensitivity Reactions to Biologic Agents
Vultaggio, A., & Castells, M. (2014) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2014.04.008 · Cited by 50
Oh, K., Oh, E. H., Baek, S., Song, E. M., Kim, G., Seo, M., Hwang, S. W., Park, S. H., Yang, D., Kim, K., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179266 · Cited by 46
Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.
Armstrong, A. W., Vender, R. B., & Kircik, L. (2016) · Europe PMC (PubMed Central) · Cited by 35
Strober, B. E., Langley, R. G. B., Menter, A., Magid, M., Porter, B. L., Fox, T., Safi, J., & Papavassilis, C. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16051 · Cited by 20
Self-citationKlein, U., Liang, E. C. Z., Vogel, B., Kolbinger, F., Bruin, G. J. M., & Lloyd, P. M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-eular.1868 · Cited by 10
Cited by
Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata‐Csörgö, Z., Boonen, H., De Jong, E., Garcia‐Doval, I., Gisondi, P., Kaur‐Knudsen, D., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16915 · Cited by 420
Self-citationMcInnes, I. B., Behrens, F., Mease, P. J., Kavanaugh, A., Ritchlin, C., Nash, P., Masmitja, J. G., Goupille, P., Korotaeva, T., Gottlieb, A. B., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30564-x · Cited by 279
Self-citationMcGonagle, D. G., McInnes, I. B., Kirkham, B. W., Sherlock, J., & Moots, R. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215356 · Cited by 254
Self-citationBerry, S. P. D.-G., Dossou, C., Kashif, A., Sharifinejad, N., Azizi, G., Hamedifar, H., Sabzvari, A., & Zian, Z. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108402 · Cited by 124
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
Zwicky, P., Unger, S., & Becher, B. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191123 · Cited by 91
Metadata
- Authors
- Deodhar, A., Mease, P. J., McInnes, I. B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., Pricop, L., & Fox, T.
- Venue
- Arthritis Research & Therapy
- Published
- 2019-05-02
- Volume
- 21
- Issue
- 1
- Pages
- 111-111
- ISSN
- 1478-6354 (ISSN-L)
- 1478-6362
- OpenAlex
- W2947452967
- Cited by
- 292
- References
- 47
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.